Rodos BioTarget (RBT) is a biopharmaceutical company developing a targeted drug delivery platform. RBT’s patented TargoSphere® technology enables carrying a broad range of active agents selectively into the center of the immune response - i.e., directly into antigen-presenting cells. RBT currently applies its TargoSphere® technology successfully in various models of infectious diseases caused by viruses like HCV/ Hepatitis C and HIV/ AIDS and by bacteria like in Tuberculosis, Legionellosis, and MRSA. Yet, any disorder that goes along with either overshooting or insufficient immunity caused by antigen-presenting cells - like chronic inflammations, cancers, allergies, and autoimmune diseases - may be addressed by RBT’s TargoSphere® technology.

Institut National de la Sant? et de la Recherche M?dicale provides medical services. The firm specializes in biomedical research and public health research. The company is headquartered in Paris, Cedex, France.

Seoul National University Hospital (서울대학교병원) is one of the oldest and biggest hospitals in South Korea. It is a general and teaching hospital of Seoul National University's College of Medicine. Except SNUH Healthcare System Gangnam Center, all branches have an emergency department (ED).

NH TherAguix SAS operates as a biotechnology company. The firm develops a nanodrug against cancer called AGuIX based on nanometric structuring that allows intravenous injection and the combination of the following properties to fight tumors: targeting, imaging, and treating. The company was founded by G��raldine Le Duc, Olivier Tillement and Fran��ois Lux in on December 11, 2015 and is headquartered in Meylan, France.

FAPESP is a public foundation, funded by the taxpayer in the State of São Paulo, with the mission to support research projects in higher education and research institutions, in all fields of knowledge. São Paulo has a population of forty million and generates 35% of Brazil’s GNP. The constitution of the State establishes that 1% of all state taxes belong to the foundation and the government transfers these funds monthly. The stability of the funding and the autonomy of the foundation allow for an efficient management of the resources that has had a sizable impact: while São Paulo has 22% of the Brazilian population and 30% of the scientists with a doctorate in the country, the state responds for 52% of the country’s scientific articles published in international journals. The Foundation works in close contact with the scientific community: all proposals are peer reviewed with the help of area panels composed of active researchers. Besides funding research in all fields, the foundation supports large research programs in Biodiversity, Bioenergy, Global Climate Change, and in Neurosciences.

Nanosion Co. Ltd. is a company that conduct the research and development of nanomedicines formulated by nanotechnology (diagnostic agent, therapeutic agent, pain relief agent against cancer).

CytImmune Sciences, Inc. created a first-in-class, patented nanomedicine platform, Aurimune™. All Aurimune products seek out and destroy the blood vessels inside any primary or metastatic solid tumor. Tumor blood vessel destruction alters the tumor microenvironment in a way that significantly improves the effectiveness of other therapies including chemotherapies, radiation therapies and immunotherapies. CYT-6091, the first generation Aurimune nanomedicine and a first-in-class therapeutic, was shown to be safe and tumor-targeted in a Phase I Clinical Trial. CytImmune is raising funds to advance CYT-6091 through Clinical Trials. All Aurimune™ products are built around a 27nm gold nanoparticle core. Gold is known to be safe, has a flexible chemistry including forming covalent bonds, and can be manufactured with scale and precision in GMP conditions. All Aurimune products carry Tumor Necrosis Factor Alpha (TNF). Additionally, CytImmune developed a patented gold pegylation technology to prevent Aurimune removal by the immune system. This stealth attribute allows Aurimune to remain in circulation long enough to concentrate inside solid tumors. The Aurimune family of nanomedicines includes CYT-6091 and several second generation, multifunctional nanomedicines. Second generation nanomedicines use TNF to destroy tumor blood vessels, then deliver anti-cancer agents including chemotherapies and targeted biologics into the tumor. Preclinical data indicate this approach concentrates anti-cancer therapies inside solid tumors, which dramatically increases effectiveness while reducing drug-related side effects. Therapeutics delivered by second generation Aurimune products include: • Common Small Molecule Chemotherapies: Paclitaxel, Doxorubicin, Gemcitabine • Targeted Therapies and Biologics: TNF, Interferon Gamma, Mono and Bi-valent SMAC Memetics

Wuxi Zhongke Guangyuan Biomaterials Co., Ltd., established on 2008-07-24, Business scope includes licensed projects:Production of Class II Medical Devices;Production of Class III Medical Devices(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results) General project:Sales of bio-based materials;Import and export;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Production of Class I Medical Devices(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

SynerGene Therapeutics is a biotechnology company with focuses on developing gene-based nanotech cancer therapeutics and diagnostics. It was incorporated in 1998 and is based in Potomac, Maryland.

The Nanjing General Hospital of People's Liberation Army (NGH; Chinese: 中国人民解放军南京总医院), formerly Nanjing General Hospital of Nanjing Military Command (Chinese: 中国人民解放军南京军区南京总医院), or Nanjing General Hospital, The Military General Hospital, is also known as Jinling Hospital (formally Jinling Hospital of the Medical School of Nanjing University) which used to be Central Hospital. NGH is located at 305 Zhongshan East Road, Nanjing, Jiangsu Province, China. It is a large comprehensive teaching hospital integrating medical services with teaching and research.

Seoul National University Bundang Hospital (분당 서울대병원) is located in Gumi-dong, Bundang, Seongnam, Gyeonggi-do, South Korea. It began its first treatment on 10 May 2003. It was set up due to a rapid increase in demand for geriatric treatment and the government's request for the establishment of a medical facility for local residents.

The University of California is the nation's best public university system, delivering top-notch research and innovation to California (and the world).

Longhua Hospital Shanghai University of TCM, a subsidiary of Shanghai University of Traditional Chinese Medicine, is a company headquartered in Shanghai, China. The firm provides hospital services.

Beijing High Energy Xingyuan Hotel Co., Ltd., established on 1985-06-01, Business scope includes accommodation;Chinese food;haircut;retail bakery,Dried and Fresh Fruits,drinks,liquor,cigarette;laundry;retail general merchandise.(Market entities independently choose business projects in accordance with the law,Carry out business activities;Items subject to approval by law,Carry out business activities in accordance with the approved content after approval by relevant departments;Do not engage in the business activities of projects prohibited and restricted by the industrial policies of the state and this city.)